Privileged and Confidential
Attorney-Client Communication
American Academy of Dermatology Association
Board of Directors Meeting
Rosemont, Illinois
May 16, 2015

Present
Mark Lebwohl, MD, President
Timothy G. Berger, MD, Vice President
Abel Torres, MD, JD, MD, President-Elect
Kenneth J. Tomecki, MD, Vice President-Elect
Brett M. Coldiron, MD, Immediate Past President
Suzanne M. Olbricht, MD, Secretary-Treasurer
Barbara M. Mathes, MD, Assistant Secretary-Treasurer
Neal D. Bhatia, MD
Marc D. Brown, MD
Kevin D. Cooper, MD
Sheila Fallon Friedlander, MD
Jane M. Grant-Kels, MD
Janet G. Hickman, MD
Julie A. Hodge, MD, MPH
George J. Hruza, MD
Mark D. Kaufmann, MD
Carrie A. Kovarik, MD
Stephen H. Mandy, MD
Jack S. Resneck, Jr., MD
Kathryn Schwarzenberger, MD
Paul A. Storrs, MD
Gary S. Wood, MD
Robert D. Durst Jr., MD
Sabrina Newman, MD, Incoming Young Physicians Board Observer

Not Present:
Robert T. Brodell, MD
Nathaniel Miletta, MD, Residents/Fellows Board Observer
Andreas D. Katsambas, MD, International Board Observer

Speakers / Guests
Marta J. Van Beek, MD, MPH, Chair, Council on Government Affairs, Health Policy and Practice
James S. Taylor, MD, Co-Chair, Ad Hoc Task Force on Data Collection Platform and Registries

Staff
Elaine Weiss, JD, Executive Director and CEO
Robert M. Portman, JD, General Counsel
Sarah Tancredi, MBA, PHR, Managing Director, Administration
Steve Debnar, Chief Financial Officer
Barbara Greenan, Sr. Director, Advocacy & Policy
Krista D. Kauper, Sr. Director, Constituent Relations & Strategic Planning
Cindy Kuhn Sr., Director, Membership Engagement
Melanie Tolley Hall, Sr. Director, Integrated, Communications
Cyndi Del Boccio, Director, Executive Office
Roseanne Fischoff, MPP, Director, Science, Quality & Practice
Erik Horn, Director, Information Technology
SUMMATION REPORT
AADA BOARD OF DIRECTORS MEETING
MAY 16, 2015
PAGE 2 OF 5

Beth Laws, Director, Advocacy and Policy Operations
Leslie Stein-Lloyd, JD, Director, Regulatory & Payment Policy
Suzanne Lothary, MBA, Director, Marketing
Lara Lowery, Director, Creative and Publishing
Tim Moses, CMP, Director, Meetings and Conventions
Jennifer Thompson, Senior Manager, Live Education
Kristina Finney, Manager, Quality and Patient Safety Resources
Jose Moyano, Manager, Clinical Practice Guidelines & Policy Development

CALL TO ORDER
Mark Lebwohl, MD, President and presiding, called the meeting of the Board of Directors of the American Academy of Dermatology Association to order at 9:03 AM (CDT) on Saturday, May 16, 2015. Dr. Lebwohl welcomed the Board members and the observers and guests.

QUORUM
Suzanne M. Olbricht, MD, Secretary-Treasurer declared that a quorum was present for the transaction of business.

ORDER OF BUSINESS/INTRODUCTORY MATTERS
Antitrust Compliance Policy, Fiduciary Obligations, and Note Taking
Dr. Lebwohl referred the Board members to the printed materials regarding the AAD/A Antitrust Compliance Policy and note taking during meetings and reminded them about the importance of following their fiduciary obligations, including maintaining confidentiality and declaring conflicts of interest.

Disclosure of Conflicts of Interest and Code of Conduct
The Board members’ disclosures of potential conflicts of interest and code of conduct were circulated. Dr. Olbricht asked Board members to update their disclosures and to declare any other actual or potential conflicts of interest with respect to specific agenda items for this meeting.

Separate Order of Business
Mr. Portman reminded the Board members that they would follow the American Institute of Parliamentarians Standard Code of Parliamentary Procedure (formerly Sturgis Code of Parliamentary Procedure) and that it is essential that the Academy follow the order of business and observe corporate formalities necessary to ensure the separateness of the two organizations.

Review and Approval of Academy Board of Directors Board Minutes, and Executive Committee Summation Report
Dr. Olbricht presented the minutes of the March 23, 2015 Board meetings (as amended to add Paul Storrs’ name).

A motion was made and duly seconded to approve the Board minutes of the March 23, 2015 meeting (with Paul Storrs name added to the attendee list).

ACTION: Approved
AADA Strategic Discussion

King v Burwell: ACA Subsidies Case
Dr. Van Beek gave report on potential implications of the Supreme Court’s decision in King v. Burwell. This case challenges the Obama Administration’s interpretation of the Affordable Care Act (ACA) to allow it to pay federal subsidies to enrollees in states that do not have their own exchanges. If Court rules for Burwell, all subsidies will remain in place. If Court rules for King, subsidies in 37 states will be in jeopardy. Some legislative fixes have already been proposed. The decision will also spur more attempts to repeal the ACA.

Dr. Resneck reported the American Medical Association is in a wait-and-see position and has not taken a position on this case. AAD members seem to be split on the case. He noted that if the court rules for King, there may be an opportunity to revisit concerns about parts of the law that physicians do not like.

The Board discussed the need for a survey on how the ACA has affected dermatologists—positive or negative.

The AADA Board recessed at 9:19 AM (CDT) to reconvene the AAD Board Meeting.

The AADA Board reconvened at 4:20 PM (CDT).

OFFICER AND DIRECTORS REPORTS
Dr. Lebwohl reminded the Board that his report, the Secretary-Treasurer’s report, the Executive Director’s report, and the Board Observers’ reports were presented during the Academy Board meeting.

American Medical Association Relative Value Scale Update Committee (RUC) Report
Dr. Mark Kaufmann provided the RUC report.

A motion was made and duly seconded to approve the AMA RUC report for information only and that the Association takes the same actions as were taken by the Academy Board of Directors for the other reports.

ACTION: Approved

NEW BUSINESS

Council on Government Affairs, Health Policy & Practice (GAHPP)
Position Statement on Teledermatology
Dr. Resneck stated after the Board of Directors approved an updated Position Statement on Teledermatology on August 9 2014, a group of concerned members sent a recommendation for action (RFA) to the Teledermatology Task Force (TTF). The recommendation worked its way through the TTF, the Access to Dermatologic Care Committee (ADCC) and up to the Council on Government Affairs, Health Policy, and Practice (GAHPP) and was not approved by the Council on GAHPP in fall 2014. The Council on GAHPP provided instruction that the TTF look at options for compromised language which could be added.

Following a Teledermatology Multi-stakeholder Roundtable meeting on March 19 and the TTF in-person meeting on March 20, the TTF approved compromise language to address concerns raised in the previously discussed RFA. The Telemedicine Task Force, the Access to Dermatologic Care
Committee and Council on Government Affairs, Health Policy, and Practice all voted to approve this additional language. The TTF will continue to engage stakeholders to facilitate dialogue on this subject matter and work diligently to protect the high quality of the Position Statement on Teledermatology, which supports dermatology leadership in the telemedicine space.

A motion was made and duly seconded to approve the additional language to the Position Statement on Teledermatology. “There are differences between care delivered via teledermatology and care delivered in person, both of which are advantageous in different care circumstances”

**ACTION:** Approved

**Health Policy Retreat**
Drs. Van Beek and Schwarzenberger reported on the discussion of alternative payment model (APM) options for dermatology at the health policy retreat the day before. The AADA is working with Healthsperien regarding the feasibility of these options and member needs.

**Dermatology Lab Accreditation**
Dr. Grant-Kels stated that the Dermatopathology Rapid Response Committee (DPRRC) elected to gauge interest from the general membership through the recent 2014 AAD/A Dermatopathology Survey. The survey results indicated two key findings on this issue:

1. 12% have in-office labs; though it varies by dermatology practice size and type too; Majority of respondents expressed an interest in an AAD/A lab accreditation program, with 80% indicating support for an AAD/A accreditation program.
2. Majority (84%) of members with in-office dermatopathology labs indicated that they comply with Clinical Laboratory Improvement Act (CLIA) requirements, while 9% indicated they go above and beyond by accrediting with the College of American Pathologists (CAP) or other lab accreditors, and 8% indicated that they did not know.

She noted that this strategy would address dermatology office lab accreditation in light of ongoing pressures from payers for this requirement, such as United Healthcare (UHC) launching its Laboratory Benefit Management Program (LBMP) pilot in Florida on April 15, 2015, which requires CAP or Joint Commission lab accreditation. She reported that UHC indicated that it intends to launch similar pathology lab management programs in other states (namely, Texas and North Carolina). This may lead other private payers and national labs to roll out similar lab management programs throughout the country.

A motion was made and duly seconded to approve the following two-part strategy:

**Short-Term Strategy:**
Explore partnering with CAP [or other accreditors] on a joint “pathway” program tailored to dermpath physician-owned labs (POL); conceivably this may involve working with an accrediting “partner” in a “hands-on” capacity to customize dermatopathology educational outreach and compliance support resources to help the client POL achieve and maintain accreditation.

**Long-Term Strategy:**
Consider setting up an AAD lab accreditation program from scratch, which would depend on obtaining deemed status authorization from Centers for Medicare & Medicaid Services based on program being equal to or more stringent than the CLIA regulations, and equal to but more streamlined than the CAP regulations.
Organizational Structure Committee
Council on Government Structure Committee
Dr. Olbricht reported that the newly converted Drug Pricing and Transparency Task Force would be charged to focus on issues related to the increase in drug prices, the cost of specialty medications and work to ensure price transparency for patients and physicians.

A motion was made and duly seconded to approve converting the Ad Hoc Task Force on Drug Pricing and Transparency into the Drug Pricing and Transparency Task Force reporting to the Regulatory Policy Committee, its mission and composition.

ACTION: Approved

A motion was made and duly seconded that the AADA take the same action as the AAD regarding any issues of common interest or concern and also accept the Consent Reports as presented.

March 20, 2015 SkinPAC
March 19, 2015 Priorities Committee

ACTION: Approved

ADJOURNMENT
There being no further business, Dr. Lebwohl adjourned the AADA Board of Directors Meeting at 4:45 PM (CDT).

Respectfully Submitted,

Suzanne M. Olbricht, MD, FAAD
Secretary-Treasurer